REG - Eco Animal Health Gp - Risk Profile Demonstrated for ECOVAXXIN MS

ECO Animal HealthAnnouncement

08/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240508:nRSH4276Na&default-theme=true

RNS Number : 4276N  Eco Animal Health Group PLC  08 May 2024

8 May 2024

 

 

 

 

ECO Animal Health Group plc

("ECO" or the "Company")

 

ECO Animal Health Mycoplasma synoviae vaccine for poultry, ECOVAXXIN(®) MS
demonstrates favourable risk profile

-     Favourable internal risk assessment reviewed by the United States
Department of Agriculture is key to US approval

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health
company with a portfolio of marketed veterinary products and a maturing
proprietary R&D pipeline, announces that ECOVAXXIN(®) MS, its new live
vaccine against Mycoplasma synoviae in poultry, is a step closer to approval
by the United States Department of Agriculture (USDA) after internal risk
assessments demonstrated that the vaccine does not revert to virulence.

Mycoplasma synoviae is a bacterium that can cause respiratory disease and
synovitis in chickens and may have deleterious effects on egg production.

Demonstrating that a vaccine strain does not regain virulence after passages
through poultry is part of the risk assessment required to obtain a license
for the vaccine in the US. These data demonstrating a lack of reversion to
virulence have been reviewed by the USDA, which found the study methodology
and data acceptable to support the safety of the vaccine strain.

The vaccine project is the result of a collaboration between ECO and Professor
Naola Ferguson-Noel of the Poultry Diagnostic & Research Center, College
of Veterinary Medicine at the University of Georgia (UGA), USA. The vaccine
strain is a non-pathogenic Mycoplasma synoviae isolate and has been shown
previously to be free of antimicrobial resistance (AMR) genes - a prerequisite
for US registration.

ECO is working in close collaboration with the USDA for the licensure of its
vaccine against Mycoplasma synoviae and to gain authorization to import and
distribute the product in the US.

ECO is targeting a launch of ECOVAXXIN(®)MS in the US from late 2025.

David Hallas, CEO of ECO, commented: "ECO is focused on building a robust and
long-lasting R&D pipeline, and providing the poultry industry with a safe
and effective new vaccine against Mycoplasma synoviae is a key element of
this. ECOVAXXIN(®) MS is the first step in strengthening ECO's ambition to
launch multiple vaccine products in key territories."

"This risk assessment demonstrates that ECO can meet the robust safety
threshold set out by the USDA and shows that we are taking the right steps
towards obtaining a critical US license."

-Ends-

For further information please contact:

 

 ECO Animal Health Group plc                                    020 8447 8899

 David Hallas (CEO)

 Christopher Wilks (CFO)
 Singer Capital Markets (Nominated Adviser & Joint Broker)      020 7496 3000

 Phil Davies

 Sam Butcher
 Investec (Joint Broker)                                        020 7597 5970

 Gary Clarence

 Lydia Zychowska
 Equity Development                                             020 7065 2692

 Hannah Crowe

 Matt Evans
 ICR Consilium (Financial PR)                                   020 3709 5700

 Mary-Jane Elliott                                              ecoanimalhealth@consilium-comms.com

 Jessica Hodgson

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing
branded veterinary pharmaceuticals globally, with expertise in antibiotics and
vaccines for pigs and poultry. We have a maturing proprietary R&D
pipeline.

Headquartered in the UK, with global offices including R&D and
manufacturing, we have marketing authorisations in over 70 countries and
employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is
effective against both respiratory and intestinal diseases in pigs and
poultry.

Click here for more information: https://ecoanimalhealth.com
(https://ecoanimalhealth.com)

( )

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCQKOBNCBKKQPK